Oculus Innovative Sciences, Inc. Announces a Multi-Year Licensing Agreement With Eloquest Healthcare(R) for Microcyn(R)-Based Wound Care Products Jul 27, 2011
Oculus Innovative Sciences Announces Fiscal First Quarter 2012 Financial Results and Conference Call Jul 21, 2011
AmDerma Pharmaceuticals Exercises Option to License Rights to Oculus Innovative Sciences Microcyn(R)-Based Acne Drug Candidate Jun 28, 2011
Oculus Innovative Sciences Reports Record Fourth Quarter, Beating Quarterly Guidance; and Reports Year-End Revenue for Fiscal Year Ended March 31, 2011 Jun 2, 2011
Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2011 Financial Results and Conference Call May 25, 2011
Oculus Innovative Sciences Beats Fourth Quarter Guidance and Provides Commercialization Update May 10, 2011
Oculus Innovative Sciences Posts CEO's Presentation From the Roth Capital Partners 23rd Annual Growth Stock Conference Mar 24, 2011
Amneal and Oculus Innovative Sciences Announce Broad Multi-Market, Multi-Product Collaboration for Microcyn(R)-Based Drugs and Devices Feb 15, 2011
Oculus Innovative Sciences Receives New FDA 510(k) Clearance for Microcyn-Based Dermatology HydroGel for Management of Atopic Dermatitis, Radiation Dermatitis and Other Skin Dermatoses Feb 8, 2011
Oculus Innovative Sciences Reports Record Third Quarter Revenue for Fiscal Year 2011, Exceeding Guidance Feb 3, 2011
